Perrigo's revenues jumped with its Elan buyout; Shire bails on Vyvanse as a depression treatment;

@FiercePharma: AbbVie is hit with 5 lawsuits citing the dangers of its 'low T' drug. News | Follow @FiercePharma

@TracyStaton: Perhaps not coincidentally, best-read special report: Top 10 pharma layoffs of 2013. Report | Follow @TracyStaton

@EricPFierce: It is litigation seminar for pharma today. Roche halting Mylan's biosimilar launch, Abbvie sued over AndroGel & more. | Follow @EricPFierce

> Perrigo ($PRGO), which laid out $8.6 billion last year to buy Elan ($ELN) and its low-tax Irish address, reported record earnings. Release

> Shire ($SPHG) has stopped development of its ADHD drug Vyvanse as a treatment for depression after it failed in two late-stage trials. Story

> A congresswoman has told the FDA she thinks its efforts to speed drug approvals is putting patients at risk. Story

> India is looking to issue a compulsory license for Bristol-Myers Squibb's ($BMY) leukemia drug Sprycel. Story

> The FDA says its efforts to fight drug shortages in the U.S. are paying off. Report

Medical Device News

@FierceMedDev: Myriad Genetics' performance and M&A plans produce investor bliss. Story | Follow @FierceMedDev

@MarkHFierce: Scottish startup Edinburgh Molecular Imaging pulled in more than $6.5 million in Series A financing. Release | Follow @MarkHFierce

@MichaelGFierce: Hot on FierceDrugDelivery: Pfizer snags electroporation device license from Ichor for cancer vaccine delivery. News | Follow @MichaelGFierce

@EmilyWFierce: Insulet packing up camp, making room for expansion. Article | Follow @EmilyWFierce

> LabCorp eked out year-end growth while Dx reimbursement problems remained. Report

> Sorin touts a big Q4 earnings boost in preliminary results. More

> FDA: Guidance for medical device interoperability standards is on its way. Item

Biotech News

@FierceBiotech: Biotech VC Clarus reaches for $375M in its latest fund. Story | Follow @FierceBiotech

@JohnCFierce: Martoma guilty in the bapineuzumab insider trading case. Can't say I'm surprised. They had him cold. Story via NYT | Follow @JohnCFierce

@DamianFierce: Biotech IPOs: $500M in a single week should accelerate some R&D efforts. More | Follow @DamianFierce

@EmilyMFierce: Stem cell lines not fit for clinic. Story via The Scientist | Follow @EmilyMFierce

> U.S. rep rips the FDA's efforts to speed up drug approvals. Story

> Despite pomp and circumstance, 2014's looking short on blockbusters. More

And Finally... Germany's Boehringer Ingelheim has become a corporate member of the U.S. Hispanic Chamber of Commerce and will partner with the group to raise awareness of chronic diseases like diabetes. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.